These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 12547847)

  • 1. Acarbose improves glycemic control in overweight type 2 diabetic patients insufficiently treated with metformin.
    Phillips P; Karrasch J; Scott R; Wilson D; Moses R
    Diabetes Care; 2003 Feb; 26(2):269-73. PubMed ID: 12547847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study.
    Halimi S; Le Berre MA; Grangé V
    Diabetes Res Clin Pract; 2000 Sep; 50(1):49-56. PubMed ID: 10936668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and tolerability of acarbose in Asian patients with type 2 diabetes inadequately controlled with diet and sulfonylureas.
    Lin BJ; Wu HP; Huang HS; Juang JH; Sison A; bin Abdul Kadir DK; Cho CG; Sridama W;
    J Diabetes Complications; 2003; 17(4):179-85. PubMed ID: 12810240
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison.
    Wang JS; Lin SD; Lee WJ; Su SL; Lee IT; Tu ST; Tseng YH; Lin SY; Sheu WH
    Clin Ther; 2011 Dec; 33(12):1932-42. PubMed ID: 22078152
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
    Roberts VL; Stewart J; Issa M; Lake B; Melis R
    Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolic effect of repaglinide or acarbose when added to a double oral antidiabetic treatment with sulphonylureas and metformin: a double-blind, cross-over, clinical trial.
    Derosa G; Salvadeo SA; D'Angelo A; Ferrari I; Mereu R; Palumbo I; Maffioli P; Randazzo S; Cicero AF
    Curr Med Res Opin; 2009 Mar; 25(3):607-15. PubMed ID: 19232035
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study.
    Williams-Herman D; Johnson J; Teng R; Luo E; Davies MJ; Kaufman KD; Goldstein BJ; Amatruda JM
    Curr Med Res Opin; 2009 Mar; 25(3):569-83. PubMed ID: 19232032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes.
    Rosenstock J; Brown A; Fischer J; Jain A; Littlejohn T; Nadeau D; Sussman A; Taylor T; Krol A; Magner J
    Diabetes Care; 1998 Dec; 21(12):2050-5. PubMed ID: 9839093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acarbose improves glycemic control in insulin-treated Asian type 2 diabetic patients: results from a multinational, placebo-controlled study.
    Hwu CM; Ho LT; Fuh MM; Siu SC; Sutanegara D; Piliang S; Chan JC;
    Diabetes Res Clin Pract; 2003 May; 60(2):111-8. PubMed ID: 12706319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of acarbose and metformin in patients with Type 2 diabetes mellitus insufficiently controlled with diet and sulphonylureas: a randomized, placebo-controlled study.
    Willms B; Ruge D
    Diabet Med; 1999 Sep; 16(9):755-61. PubMed ID: 10510952
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acarbose in NIDDM patients with poor control on conventional oral agents. A 24-week placebo-controlled study.
    Lam KS; Tiu SC; Tsang MW; Ip TP; Tam SC
    Diabetes Care; 1998 Jul; 21(7):1154-8. PubMed ID: 9653611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The synergistic effect of miglitol plus metformin combination therapy in the treatment of type 2 diabetes.
    Chiasson JL; Naditch L;
    Diabetes Care; 2001 Jun; 24(6):989-94. PubMed ID: 11375358
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.
    Wang W; Ning G; Ma J; Liu X; Zheng S; Wu F; Xu L; O'Neill EA; Fujita KP; Engel SS; Kaufman KD; Shankar RR
    Curr Med Res Opin; 2017 Apr; 33(4):693-699. PubMed ID: 28035868
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective, parallel group, open-labeled, comparative, multi-centric, active controlled study to evaluate the safety, tolerability and benefits of fixed dose combination of acarbose and metformin versus metformin alone in type 2 diabetes.
    Jayaram S; Hariharan RS; Madhavan R; Periyandavar I; Samra SS
    J Assoc Physicians India; 2010 Nov; 58():679-82, 687. PubMed ID: 21510461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Acarbose on Glycemic Variability in Patients with Poorly Controlled Type 2 Diabetes Mellitus Receiving Stable Background Therapy: A Placebo-Controlled Trial.
    Derosa G; Franzetti I; Querci F; D'Angelo A; Maffioli P
    Pharmacotherapy; 2015 Nov; 35(11):983-90. PubMed ID: 26598090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients.
    Del Prato S; Erkelens DW; Leutenegger M
    Acta Diabetol; 2003 Mar; 40(1):20-7. PubMed ID: 12682825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acarbose and metabolic control in patients with type 2 diabetes with newly initiated insulin therapy.
    Schnell O; Mertes G; Standl E;
    Diabetes Obes Metab; 2007 Nov; 9(6):853-8. PubMed ID: 17924867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The beneficial effect of α-glucosidase inhibitor on glucose variability compared with sulfonylurea in Taiwanese type 2 diabetic patients inadequately controlled with metformin: preliminary data.
    Lin SD; Wang JS; Hsu SR; Sheu WH; Tu ST; Lee IT; Su SL; Lin SY; Wang SY; Hsieh MC
    J Diabetes Complications; 2011; 25(5):332-8. PubMed ID: 21813293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of acarbose in the treatment of Type 2 diabetes: data from a 5-year surveillance study.
    Mertes G
    Diabetes Res Clin Pract; 2001 Jun; 52(3):193-204. PubMed ID: 11323089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.